rethinkTHC Search
Menu
Study breakdown

Low-dose THC boosted dopamine and GABA in the brain's reward center, while high doses decreased dopamine in mice

Animal StudyModerate evidence
The takeaway

In mice, low-dose THC increased dopamine and GABA in the nucleus accumbens shell while high doses decreased dopamine, and a partial CB1 agonist (AM11101) produced neither reward-related neurochemical changes nor place preference.

Neuroscience researchers, people interested in how cannabis affects the brain's reward system, and pharmacologists developing cannabinoid-based therapeutics.

Low-dose THC: dopamine up. High-dose THC: dopamine down.

What the researchers found

Low-dose THC increased dopamine and GABA in the nucleus accumbens shell, while high-dose THC decreased dopamine. The full CB1 agonist AM8936 increased all three neurotransmitters at low doses. The partial agonist AM11101 failed to substantially alter any neurotransmitter and did not produce conditioned place preference, suggesting it lacks rewarding properties.

Why it matters

Understanding how cannabinoids affect the dopamine-GABA-glutamate balance in reward circuits is fundamental to understanding both cannabis addiction potential and the development of CB1-based therapeutics that might treat pain without producing reward.

The numbers in context

Three CB1 agonists tested: THC (natural), AM11101 (partial synthetic), AM8936 (full synthetic). Neurotransmitter monitoring for 5 hours post-injection. THC and AM8936 produced conditioned place preference; AM11101 did not. Correlation analysis revealed DA-GABA and Glu-GABA relationships for THC at early time points.

How the study worked

In vivo microdialysis combined with liquid chromatography-mass spectrometry in male mice, measuring dopamine, glutamate, and GABA in the nucleus accumbens shell for 5 hours after single intraperitoneal injections of THC, AM11101, or AM8936. Conditioned place preference testing assessed rewarding effects.

What this study cannot tell us

Mouse study using only male animals. Single-dose design does not capture chronic exposure effects. Synthetic agonists may not perfectly model natural cannabis use. Nucleus accumbens shell is one of several reward-related regions.

How to read the evidence

Moderate: rigorous neuroscience methodology with in vivo microdialysis and behavioral testing, but limited to male mice with single-dose design.

When this study was published

Published 2026.

The bigger picture

The divergent dose-response pattern (low-dose dopamine increase, high-dose decrease) helps explain why cannabis can feel rewarding at lower doses but aversive at higher ones. The finding that partial CB1 agonists avoid reward-related effects could guide development of non-addictive cannabinoid medications.

Questions still open

  • Would female mice show different neurotransmitter patterns? Do these dose-response relationships translate to the human reward system? Could partial CB1 agonists like AM11101 provide pain relief without addiction risk?

Common questions

How does THC affect dopamine in the brain?
In this mouse study, low doses of THC increased dopamine and GABA in the nucleus accumbens shell (a reward center), while high doses decreased dopamine, suggesting a dose-dependent shift from rewarding to potentially aversive effects.
Are all cannabinoid drugs equally rewarding?
No. The partial CB1 agonist AM11101 did not alter reward-related neurotransmitters or produce place preference in mice, unlike THC and the full agonist AM8936, suggesting partial agonists may avoid addictive properties.

Read the original research

Dopamine, γ-aminobutyric acid, and glutamate balance in the nucleus accumbens shell: Differential effects of cannabinoid 1 receptor agonists Δ9-Tetrahydrocannabinol, AM11101, and AM8936.

Neuropharmacology, 110891

Citation

Smith, Evan C; Iliopoulos-Tsoutsouvas, Christos; Georgiadis, Markos; Nikas, Spyros P; Brijlall, Karena; Makriyannis, Alexandros; Desai, Rajeev I. (2026). Dopamine, γ-aminobutyric acid, and glutamate balance in the nucleus accumbens shell: Differential effects of cannabinoid 1 receptor agonists Δ9-Tetrahydrocannabinol, AM11101, and AM8936.. Neuropharmacology, 110891. https://doi.org/10.1016/j.neuropharm.2026.110891

Explore the wider topic